LoadSpring Collaborates with Google Cloud and SADA to Deliver Enhanced AI Solutions
10.12.2020 19:27:00 EET | Business Wire | Press release
LoadSpring Solutions, a leading provider of global managed cloud solutions, announces a strategic collaboration with Google Cloud and SADA to provide clients with enhanced project analytics via Artificial Intelligence and Business Intelligence solutions. LoadSpring will combine its application, support, and project expertise with SADA's delivery expertise and Google Cloud infrastructure, solutions, and capabilities in AI and ML to help clients eliminate risks while increasing their insights and data access to make critical business and project decisions in real-time.
As a global leader in hosting, integrating, and providing access to software application data for project and asset-intensive organizations, LoadSpring recognizes the importance of access to a global technology footprint. Its customers operate worldwide and expect the same performance and support, whether in the Americas, Europe, the Middle East, or Pan-Asia. The new alliance will accelerate customer benefits, including one-stop managed cloud services, centralized support, and improved project command and control through LoadSpring Cloud Platform.
"The strategic alignment between our organizations is significant. The investments Google Cloud, SADA, and LoadSpring, are making to deliver best-in-class cloud solutions is transformational for our clients. I'm truly excited about the prospect of hosting, accessing, and leveraging years of data during the project life-cycle," said Dean Edmundson, Chief Strategy Officer at LoadSpring.
"Organizations today have an opportunity to transform business processes and derive more value out of their data with cloud capabilities in AI, ML, and analytics," said Dave Hutchison, Managing Director, Worldwide Channels at Google Cloud. "We are excited that LoadSpring and SADA will collaborate to help businesses leverage Google Cloud infrastructure and technologies to do so, and look forward to working together to drive digital transformation."
"We're excited to partner with LoadSpring to help them maximize the value of their Google Cloud investment," stated Simon Margolis, VP of CE, SADA. "The combined strength of our offerings will help clients expand their cloud, Business Intelligence, AI, and ML capabilities to achieve better project results."
ABOUT LOADSPRING
Founded in 1999, LoadSpring is a global cloud solutions provider obsessed with offering the highest level of managed cloud services. LoadSpring delivers expert Project Management solutions and fast access to project data, Business Intelligence, and hundreds of best-of-breed project-based applications. Data safety is assured through their SOC 2 Type II security certification, providing an impenetrable cloud environment. Through their proprietary LoadSpring Cloud Platform and their soon-to-be-launched LoadSpring Marketplace, customers and partners get effortless app provisioning, higher productivity, and ROI – all while reducing the burden on their IT departments.
ABOUT SADA
SADA is a leading global provider of business and technology services empowering people to transform their work, their organizations, and the world. SADA teams have helped enterprise clients in healthcare, media, entertainment, retail, manufacturing, and the public sector achieve their boldest ambitions and solve their most complex problems. A Google Cloud Partner with multiple Specializations, SADA delivers continuous innovation, strong partnerships, and service excellence. This has led to numerous accolades and awards, including the Google Cloud Global Reseller Partner of the Year for 2018 and 2019, the Inc. 5000 Honoree list of America's Fastest Growing Private Companies for 14 straight years, and the 2020 Inc. list of America's Top 50 Workplaces. More info at www.sada.com.
For more information, contact Stacey Witt at switt@loadspring.com or visit www.loadspring.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005791/en/
Contact information
Stacey Witt
switt@loadspring.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom